Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Kristy J. Gotink(Amsterdam UMC Location VUmc), Henk M.W. Verheul(Erasmus MC)AngiogenesisDecember 10, 200910.1007/s10456-009-9160-6Cited by 488SaveCiteExport RISWatch citationsRelated PapersKinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome|Cancers|2020|18High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids|Research Square|2023|3SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma|The Oncologist|2025|0